ReaScan CXCL13 is an immunochromatographic rapid test for semiquantitative determination of chemokine CXCL13 in human cerebrospinal fluid (CSF). The test result is read from the test cassette with the ReaScan+ reader (REF 105100, Oy Reagena Ltd, Finland). The test is intended for in vitro diagnostic laboratory use by healthcare professionals.
Specificity 96 % (CSF) Sensitivity 100 % (CSF) with cut-off 250 pg/mL
ReaScan+ reader is sold separately (105100)
Haglund S et al. 2022. CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples. Eur J Clin Microbiol Infect Dis. Jan;41(1):175-179.
Ziegler et al. 2020. Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis. J Clin Microbiol. Aug 24;58(9):e00207-20.
Pietikäinen A et al. 2018. Point-of-care testing for CXCL13 in Lyme neuroborreliosis. Diagn Microbiol Infect Dis. Jul;91(3):226–228.